Septerna to Participate in Upcoming Investor Conferences
Septerna (Nasdaq: SEPN), a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, has announced its participation in two upcoming investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference on September 3 at 11:30 a.m. ET and participate in a fireside chat at the Wells Fargo Healthcare Conference on September 5 at 8:45 a.m. ET. Both presentations will be available via webcast on Septerna's website, with replays accessible for 30 days after the events.
Septerna (Nasdaq: SEPN), una società biotecnologica in fase clinica specializzata nella scoperta di farmaci mirati ai recettori accoppiati alle proteine G (GPCR), ha comunicato la sua partecipazione a due conferenze per investitori che si terranno a settembre 2025.
La società presenterà al Cantor Global Healthcare Conference il 3 settembre alle 11:30 ET e prenderà parte a una fireside chat al Wells Fargo Healthcare Conference il 5 settembre alle 8:45 ET. Entrambe le presentazioni saranno trasmesse via webcast sul sito di Septerna e le registrazioni saranno disponibili per la visione on demand per 30 giorni dopo gli eventi.
Septerna (Nasdaq: SEPN), una compañía biotecnológica en fase clínica centrada en el descubrimiento de fármacos dirigidos a receptores acoplados a proteínas G (GPCR), ha anunciado su asistencia a dos conferencias para inversores en septiembre de 2025.
La empresa presentará en la Cantor Global Healthcare Conference el 3 de septiembre a las 11:30 ET y participará en una charla informal en la Wells Fargo Healthcare Conference el 5 de septiembre a las 8:45 ET. Ambas presentaciones se emitirán por webcast en la web de Septerna y las repeticiones estarán disponibles durante 30 días tras los eventos.
Septerna (Nasdaq: SEPN)는 G 단백질 연결 수용체(GPCR) 약물 개발에 주력하는 임상 단계의 생명공학 기업으로, 2025년 9월에 열리는 두 건의 투자자 컨퍼런스에 참가한다고 발표했습니다.
회사는 9월 3일 오전 11시 30분(동부시간)에 열리는 Cantor Global Healthcare Conference에서 발표하고, 9월 5일 오전 8시 45분(동부시간)에 개최되는 Wells Fargo Healthcare Conference의 파이어사이드 채팅에 참여합니다. 두 발표 모두 Septerna 웹사이트를 통한 웹캐스트로 시청할 수 있으며, 행사 종료 후 30일 동안 재생 영상이 제공됩니다.
Septerna (Nasdaq: SEPN), une société biotechnologique en phase clinique spécialisée dans la découverte de médicaments ciblant les récepteurs couplés aux protéines G (GPCR), a annoncé sa participation à deux conférences investisseurs en septembre 2025.
La société présentera lors de la Cantor Global Healthcare Conference le 3 septembre à 11h30 ET et prendra part à une discussion informelle lors de la Wells Fargo Healthcare Conference le 5 septembre à 8h45 ET. Les deux interventions seront diffusées en webcast sur le site de Septerna et les rediffusions seront accessibles pendant 30 jours après les événements.
Septerna (Nasdaq: SEPN), ein biotechnologisches Unternehmen in klinischer Phase, das sich auf die Wirkstoffforschung für G-Protein-gekoppelte Rezeptoren (GPCR) spezialisiert hat, hat seine Teilnahme an zwei Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird am 3. September um 11:30 Uhr ET auf der Cantor Global Healthcare Conference präsentieren und am 5. September um 8:45 Uhr ET an einem Fireside-Chat auf der Wells Fargo Healthcare Conference teilnehmen. Beide Präsentationen werden per Webcast auf der Septerna-Website verfügbar sein; Wiederholungen sind bis zu 30 Tage nach den Veranstaltungen abrufbar.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September:
Cantor Global Healthcare Conference 2025
Presentation on Wednesday, September 3, 2025, at 11:30 a.m. ET
2025 Wells Fargo Healthcare Conference
Fireside chat on Friday, September 5, 2025, at 8:45 a.m. ET
Live webcasts of the presentations will be available in the investors section of the company’s website at www.septerna.com. Replays will be archived for at least 30 days following each event.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform™ is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com
Media Contact:
Carly Scaduto
carly@carlyscadutoconsulting.com
FAQ
When is Septerna (SEPN) presenting at the Cantor Global Healthcare Conference 2025?
What time is Septerna's fireside chat at the 2025 Wells Fargo Healthcare Conference?
Where can investors watch Septerna's (SEPN) conference presentations?
What is Septerna's (SEPN) main focus as a company?
